guest ::
| Home > Publications Database > Feasibility of a smartphone application for remote use in spastic ataxias: an 8-week long-term PROSPAX study. > print |
| Home > Publications Database > Feasibility of a smartphone application for remote use in spastic ataxias: an 8-week long-term PROSPAX study. > print |
| 001 | 282584 | ||
| 005 | 20251218104940.0 | ||
| 024 | 7 | _ | |a 10.1007/s00415-025-13514-1 |2 doi |
| 024 | 7 | _ | |a pmid:41342937 |2 pmid |
| 024 | 7 | _ | |a 0367-004X |2 ISSN |
| 024 | 7 | _ | |a 0012-1037 |2 ISSN |
| 024 | 7 | _ | |a 0340-5354 |2 ISSN |
| 024 | 7 | _ | |a 1432-1459 |2 ISSN |
| 037 | _ | _ | |a DZNE-2025-01344 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Willemse, Ilse H J |0 0000-0002-2095-3488 |b 0 |
| 245 | _ | _ | |a Feasibility of a smartphone application for remote use in spastic ataxias: an 8-week long-term PROSPAX study. |
| 260 | _ | _ | |a [Darmstadt] |c 2025 |b Steinkopff |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1766051324_31261 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Digital biomarkers show significant potential and are emerging as outcome measures in clinical trials in spastic ataxias (SPAX). Research on the performances of digital biomarkers in home environments remains limited.To evaluate feasibility, user adherence, time-of-day and learning effects, and consistency across settings of the SPAX-app for home monitoring in clinical trials. The app contains four tasks assessing gait, standing balance, and finger and hand movements, along with a patient-reported outcome measure (PROM).We conducted an 8-week long-term study in 38 SPAX patients and 10 healthy controls. Subjects first answered the SPAX-app PROM and performed tasks during one in-clinic session. Severity of ataxia and spasticity were assessed by clinician-reported outcome measures (ClinROs). Subjects then performed the tasks and answered the PROM twice a week in the morning and evening at home.The SPAX-app showed high feasibility for finger and hand movement tasks (92%), but limited feasibility for gait (47%) and stance (63%) tasks. Among those able to perform the tasks, adherence was high (81%). A significant difference (p < 0.01) was found between morning and evening assessments by PROMs in SPAX. Results remained stable across the day and repeated assessments, except for the inter-onset interval in finger tapping (p = 0.002 and p = 0.020, respectively). Strong correlations were observed between tasks performed at home and in the clinic. Motor outcome measures correlated well with ClinROs, but not with PROMs.The SPAX-app is a feasible tool for remote assessment in SPAX, showing high feasibility for finger and hand movement tasks, but limited feasibility for gait and stance tasks at home. Time-of-day and learning effects were minimal. Longer-term studies are needed to assess clinical relevance. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Digital biomarkers |2 Other |
| 650 | _ | 7 | |a Long-term study |2 Other |
| 650 | _ | 7 | |a Remote monitoring |2 Other |
| 650 | _ | 7 | |a Smartphone application |2 Other |
| 650 | _ | 7 | |a Spastic ataxia |2 Other |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Feasibility Studies |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Smartphone |2 MeSH |
| 650 | _ | 2 | |a Mobile Applications |2 MeSH |
| 650 | _ | 2 | |a Muscle Spasticity: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Muscle Spasticity: physiopathology |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Patient Reported Outcome Measures |2 MeSH |
| 650 | _ | 2 | |a Longitudinal Studies |2 MeSH |
| 650 | _ | 2 | |a Postural Balance: physiology |2 MeSH |
| 650 | _ | 2 | |a Young Adult |2 MeSH |
| 700 | 1 | _ | |a Mellone, Sabato |b 1 |
| 700 | 1 | _ | |a Tacconi, Carlo |b 2 |
| 700 | 1 | _ | |a Santorelli, Filippo M |b 3 |
| 700 | 1 | _ | |a Ricca, Ivana |b 4 |
| 700 | 1 | _ | |a Satolli, Sara |b 5 |
| 700 | 1 | _ | |a Klebe, Stephan |b 6 |
| 700 | 1 | _ | |a Jeschonneck, Nicole |b 7 |
| 700 | 1 | _ | |a Ilg, Winfried |b 8 |
| 700 | 1 | _ | |a Schüle-Freyer, Rebecca |0 P:(DE-2719)2812018 |b 9 |u dzne |
| 700 | 1 | _ | |a Synofzik, Matthis |0 P:(DE-2719)2811275 |b 10 |u dzne |
| 700 | 1 | _ | |a Nonnekes, Jorik |b 11 |
| 700 | 1 | _ | |a van de Warrenburg, Bart P C |b 12 |
| 773 | _ | _ | |a 10.1007/s00415-025-13514-1 |g Vol. 273, no. 1, p. 3 |0 PERI:(DE-600)1421299-7 |n 1 |p 3 |t Journal of neurology |v 273 |y 2025 |x 0367-004X |
| 856 | 4 | _ | |u https://pub.dzne.de/record/282584/files/DZNE-2025-01344%20SUP.docx |
| 856 | 4 | _ | |u https://pub.dzne.de/record/282584/files/DZNE-2025-01344_Restricted.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/282584/files/DZNE-2025-01344_Restricted.pdf?subformat=pdfa |x pdfa |
| 856 | 4 | _ | |u https://pub.dzne.de/record/282584/files/DZNE-2025-01344%20SUP.doc |
| 856 | 4 | _ | |u https://pub.dzne.de/record/282584/files/DZNE-2025-01344%20SUP.odt |
| 856 | 4 | _ | |u https://pub.dzne.de/record/282584/files/DZNE-2025-01344%20SUP.pdf |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 9 |6 P:(DE-2719)2812018 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 10 |6 P:(DE-2719)2811275 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-10 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NEUROL : 2022 |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-10 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-10 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-10 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NEUROL : 2022 |d 2024-12-10 |
| 920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser |l Parkinson Genetics |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1210000 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|